Here's Why Compugen Jumped Higher Today
Shares of Compugen (NASDAQ: CGEN) are up 20% at 2:24 p.m. EDT Tuesday after the company released encouraging data from an early-stage clinical trial testing its cancer treatment COM701.
Compugen had previously reported that nine of the first 13 patients treated in the clinical trial had stable disease, meaning their tumors weren't growing, but they didn't shrink much, either.
In the newest cohort of patients treated at a higher level, the biotech reported there was one patient with primary peritoneal cancer, a type of ovarian cancer, who had a partial response, meaning their tumor shrunk.
Source Fool.com
